|Prof. Pnina Fishman Ph.D.||Scientific Founder, Chief Exec. Officer & Director||434.15k||N/A||69|
|Mr. Motti Farbstein||Chief Operating & Financial Officer||324.33k||N/A||53|
|Dr. Ilan Cohn Ph.D.||Co-Founder & Chairman||N/A||N/A||63|
|Dr. Michael H. Silverman M.D., F.A.C.P.,FACR||Medical Director||N/A||N/A||N/A|
|Dr. Vibeke Strand M.D., FACP, FACR (USA)||Sr. Clinical Advisor||N/A||N/A||N/A|
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.
Can-Fite BioPharma Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.